Zie ook de literatuurlijsten niet-toxische middelen en behandelingen specifiek bij de verschillende vormen van kanker en bij chemo, bestraling en operaties van arts-bioloog drs. Engelbert Valstar

En weet dat u als donateur ook korting kunt krijgen op o.a. prostasol bij MEDPRO

19 november 2025: zie ook dit artikel: https://kanker-actueel.nl/NL/177lu-psma-617-naast-hormoontherapie-plus-een-hormoonreceptorremmer-arpi-verlengt-aantoonbaar-de-ziekteprogressievrije-overleving-bij-mannen-met-uitgezaaide-hormoongevoelige-prostaatkanker.html

13 november 2023: zie ook dit artikel: https://kanker-actueel.nl/theranostiek-succesvol-bij-prostaatkanker-en-schildklierkanker-lijkt-ook-interessante-behandeling-voor-borstkanker-te-kunnen-zijn-aldus-prof-dr-dalm-uit-erasmus-mc.html

28 oktober: lees ook dit artikel: https://kanker-actueel.nl/immuuntherapie-met-p-psma-101-car-t-celtherapie-gericht-op-pmsa-geeft-veelbelovende-resultaten-met-zelfs-een-complete-remissie-bij-10-zwaar-voorbehandelde-patienten-met-vergevorderde-uitgezaaide-hormoonresistente-prostaatkanker.html

28 oktober 2022: Lees ook deze nieuwe overzichtstudie hoe om te gaan met op PMSA gerichte bestraling en andere behandelingen (onderaan abstract):

Predictors and Real-World Use of Prostate-Specific Radioligand Therapy: PSMA and Beyond

PRAKTISCHE TOEPASSINGEN

Er zijn gestandaardiseerde criteria in PSMA PET/CT voor de selectie van patiënten voor 177Lu-PSMA-radionuclidetherapie (RNT) vastgesteld, maar verdere verfijning om de therapeutische respons te verbeteren is gerechtvaardigd.
Prognostische factoren voor de uitkomst na 177Lu-PSMA RNT werden geïdentificeerd en opgenomen in nomogrammen om te helpen tijdens het selectieproces van de patiënt.
Bijdragende factoren van resistentie tegen op PSMA gebaseerde RNT zijn onder meer heterogeniteit van tumor-PSMA-expressie, het niet afleveren van een dodelijke dosis straling op metastatische locaties, de micro-omgeving van de tumor en biologische radioresistentie van de tumor.
Het combineren van op PSMA gebaseerde RNT met potentieel synergetische middelen (bijv. immuuncheckpointremmers, PARP-remmers, antiandrogenen, CDK-4/6-remmer) of RNT met α-emitters kan de therapeutische respons verbeteren.
Andere biologische doelwitten dan PSMA toonden potentieel voor theranostische toepassingen bij prostaatkanker en worden momenteel onderzocht.

1 mei 2020: Aanvullend op onderstaande informatie zie ook dit studierapport: Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study.

PSMA PET / CT werd geassocieerd met een grotere nauwkeurigheid dan conventionele beeldvorming (92% versus 65%). De verbeterde nauwkeurigheid van PSMA PET / CT resulteerde in behandelingswijzigingen en een lagere blootstelling aan straling.

13 december 2019: Bron: Journal of Urology

De komst van de zogeheten Ga-PSMA-11 PET-scanning in de opsporing van uitzaaiingen van prostaatkanker bij mannen met oplopende PSA waarden heeft de praktijk van de aanpak van prostaatkanker wel veranderd. In Australië hebben ze nu 4 jaar ervaring hiermee en hebben een analyse gemaakt van totaal 191 patienten die na oplopende PSA waarden een PSMA scan / behandeling hebben gehad. De studie bevestigt in principe de nutteloosheid van het gebruik van een traditionele CT-scan en/of botscan bij uitgezaaide prostaatkanker nadat de PSA na een operatie - prostatectomie is gestegen. Zelfs bij zeer lage niveaus van PSA na de operatie, blijkt via PSMA PET-scanning alle uitzaaiingen in lymfklier, botten en viscerale tumoren te ontdekken.

Een PSMA Pet / CT scan met lutetium-177 wat ook vaak wordt gebruikt is tegelijk een behandeling omdat er gericht "bestraald" wordt op een zogeheten PSMA ligand, een eiwit dat gevoelig blijkt voor de radionuclide Gallium 68, een stofje dat gebruikt wordt in de PSMA pet / CT scan en tegelijk met de diagnose (de tumorcellen lichten op) de tumorcellen ook vernietigt.

In het Anthonius ziekenhuis in Nieuwegein werken ze ook al enkele jaren met de PSMA petscan:

"Met de PSMA PET-scan kunnen we eventuele uitzaaiingen veel eerder vaststellen. Je ziet ze al terwijl het PSA (een bepaalde eiwitwaarde in het bloed - red.) nog heel laag is", aldus Lavalaye. "Ook zien we precies waar ze zitten. Belangrijke kennis, waardoor je in veel gevallen samen met de patiënt en het behandelteam direct voor de best mogelijke behandeling kunt kiezen."
Het St. Antonius was vorig jaar het eerste Nederlandse ziekenhuis dat over de nieuwe scantechniek beschikte. "De technieken die we eerder gebruikten voor dit doel, zagen vaak afwijkingen over het hoofd", licht Lavalaye toe. "De PSMA PET-scan toont ze wél aan. Dat kan voorkomen dat we iemand onnodig gaan opereren, terwijl hij baat heeft bij een andere behandeling, zoals radiotherapie. Daarmee bespaar je de patiënt de stress van een operatie en voorkom je dat kostbare tijd verloren gaat."

Resultaten uit de Australische studie bevestigen bovenstaande:

De PSMA petscan ontdekte gelokaliseerde prostaatkanker bij 130 van 191 patiënten (68%) met PSA oplopende waarden met een mediane PSA van 1,1 ng / ml. De detectiesnelheid nam significant toe met de snelheid van oplopende PSA waarden. (p <0,001).

Met betrekking tot de PSMA petscan resultaten/ via een gecomputeriseerde tomografie had slechts 61 van 173 patiënten (35%) een ziekte die beperkt was tot het bekken, terwijl 57 van 173 patienten (33%) tumoren op afstand hadden.

De meest aangetaste lymfkliergebieden waren de obturator bij 42% en het presacrale / mesorectale gebied bij 40% van de patienten. Bij 15 van de 33 patiënten (45%) met een PSMA petscan uitslag voor en na de operatie werd ten minste 1 tumor gedetecteerd bij aanvang via de PSMA scan, 8 patienten (24%) hadden nieuwe tumoren en 10 (30%) hadden geen nieuwe uitzaaiingen volgens de PSMA petscan.

De positief voorspellende waarde van een PSMA petscan was 91%. Start van systemische therapie was significant geassocieerd / gerelateerd met uitzaaiingen op afstand gevonden door de PSMA petscan.

Het volledige studierapport: 68Ga-PSMA-11 Positron Emission Tomography Detects Residual Prostate Cancer after Prostatectomy in a Multicenter Retrospective Study is tegen betaling in te zien.

Hier het abstract van de studie:

View All Author Information

https://doi.org/10.1097/JU.0000000000000417

Abstract

Purpose:

Prostate specific antigen persistence after radical prostatectomy is associated with adverse outcomes in patients with prostate cancer. We sought to define regions at risk for residual disease as well as the accuracy of prostate specific membrane antigen ligand positron emission tomography in patients with prostate specific antigen persistence.

Materials and Methods:

At 6 participating centers a total of 191 patients who underwent 68Ga-prostate specific membrane antigen-11 positron emission tomography/computerized tomography or positron emission tomography/magnetic resonance imaging for persistently elevated postoperative prostate specific antigen (0.1 ng/ml or greater) were retrospectively included in study. The detection rate and the positive predictive value were determined. In 33 patients with additional prostate specific membrane antigen ligand positron emission tomography before prostatectomy we also determined the rate of positron emission tomography based persistence and recurrence.

Results:

Prostate specific membrane antigen ligand positron emission tomography localized prostate cancer in 130 of 191 patients (68%) with prostate specific antigen persistence at a median prostate specific antigen of 1.1 ng/ml. The detection rate significantly increased with prostate specific antigen (p <0.001). Regarding prostate specific membrane antigen positron emission tomography/computerized tomography only 61 of 173 patients (35%) had disease confined to the pelvis while 57 of 173 (33%) had distant lesions. The most frequently affected nodal regions were the obturator in 42% and the presacral/mesorectal region in 40%. In 15 of the 33 patients (45%) with prostate specific membrane antigen ligand positron emission tomography before and after surgery at least 1 lesion was detected at baseline (positron emission tomography persistence), 8 (24%) had new lesions (positron emission tomography recurrence) and 10 (30%) had negative positron emission tomography findings. The positive predictive value of prostate specific membrane antigen ligand positron emission tomography was 91%. Systemic therapy initiation was significantly associated with distant lesions on prostate specific membrane antigen ligand positron emission tomography.

Conclusions:

Prostate specific membrane antigen ligand positron emission tomography localized prostate cancer in more than two-thirds of patients with high risk features and prostate specific antigen persistence after prostatectomy. Obturator and presacral/mesorectal nodes are at high risk for persistent metastasis.

Deze volgende studie is recent gepubliceerd:

Predictors and Real-World Use of Prostate-Specific Radioligand Therapy: PSMA and Beyond

Andrei Gafita, MD1; Charles Marcus, MD2; Louise Kostos, MBBS3; David M. Schuster, MD2; Jeremie Calais, MD1; and Michael S. Hofman, MBBS4,5Show More

ABSTRACT

PSMA is a transmembrane protein that is markedly overexpressed in prostate cancer, making it an excellent target for imaging and treating patients with prostate cancer. Several small molecule inhibitors and antibodies of PSMA have been radiolabeled for use as therapeutic agents and are currently under clinical investigation. PSMA-based radionuclide therapy is a promising therapeutic option for men with metastatic prostate cancer. The phase II TheraP study demonstrated superior efficacy, lower side effects, and improved patient-reported outcomes compared with cabazitaxel. The phase III VISION study demonstrated that radionuclide therapy with β-emitter 177Lu-PSMA-617 can prolong survival and improve quality of life when offered in addition to standard-of-care therapy in men with PSMA-positive metastatic castration-resistant prostate cancer whose disease had progressed with conventional treatments. Nevertheless, up to 30% of patients have inherent resistance to PSMA-based radionuclide therapy, and acquired resistance is inevitable. Hence, strategies to increase the efficacy of PSMA-based radionuclide therapy have been under clinical investigation. These include better patient selection; increased radiation damage delivery via dosimetry-based administered dose or use of α-emitters instead of β-emitters; or using combinatorial approaches to overcome radioresistance mechanisms (innate or acquired), such as with novel hormonal agents, PARP inhibitors, or immunotherapy.

PRACTICAL APPLICATIONS

Standardized criteria in PSMA PET/CT for patient selection for 177Lu-PSMA radionuclide therapy (RNT) have been established, but further refinement to enhance therapeutic responses is warranted.
Prognostic factors for outcome after 177Lu-PSMA RNT were identified and included in nomograms to assist during the patient selection process.
Contributing factors of resistance to PSMA-based RNT include heterogeneity of tumor PSMA expression, failure to deliver a lethal dose of radiation to metastatic sites, tumor microenvironment, and tumor biological radioresistance.
Combining PSMA-based RNT with potentially synergistic agents (e.g., immune checkpoint inhibitors, PARP inhibitors, antiandrogens, CDK-4/6 inhibitor) or RNT with α-emitters may improve therapeutic responses.
Biological targets other than PSMA showed potential for theranostic applications in prostate cancer and are currently being investigated.

PSMA is a type 2 membrane glycoprotein that is expressed selectively by prostate cells, with expression level increasing dramatically in malignant prostatic tissue.1 Because of its properties, PSMA has emerged as an attractive target for theranostics in prostate cancer.2 In the past decade, numerous imaging and therapeutic radiopharmaceuticals targeting PSMA have been developed and investigated in clinical trials.3 –8 PSMA-based radionuclide therapy (RNT) is a promising therapeutic option for men with metastatic prostate cancer.5 PSMA radioligands are internalized after binding to the target, enabling delivery of radiation directly into the malignant cells.

The β-emitting radioisotope 177Lu conjugated with small molecule PSMA-617 (177Lu-PSMA-617) is the PSMA-based RNT currently furthest along in clinical development. The VISION study, an international, open-label, randomized phase III trial, demonstrated that 177Lu-PSMA-617 can prolong survival and improve quality of life when offered in addition to standard care in men with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) whose disease had progressed with taxanes and novel antiandrogens.5 In this trial, 831 patients were randomly assigned in a 2:1 ratio to 177Lu-PSMA-617 (7.4 GBq every 6 weeks for six cycles; 551 patients) plus best standard of care or standard of care alone (280 patients). The trial met both primary endpoints of overall survival (OS) and radiographic progression-free survival (PFS). The median OS was 15.3 months in the 177Lu-PSMA-617 arm versus 11.3 months in the standard of care–alone arm, resulting in a 38% reduction in the risk of death. The median radiographic PFS was 8.7 versus 3.4 months, respectively. Another randomized trial (TheraP) showed that 177Lu PSMA-617 led to higher prostate-specific antigen (PSA) response rates (66% vs. 37%), superior PFS (HR, 0.63), and fewer grade 3 or 4 adverse effects compared with cabazitaxel in men with mCRPC whose disease progressed after docetaxel.9

The U.S. Food and Drug Administration recently approved 177Lu-PSMA-617 for men with PSMA-positive mCRPC previously treated with androgen receptor–targeted agents and taxane-based chemotherapy.10 Nevertheless, a subset of patients has inherent resistance to PSMA-based RNT (approximately 30% in VISION5 and 17% in TheraP9), and acquired resistance is inevitable. Hence, strategies to increase the efficacy of PSMA-based RNT have been under clinical investigation. These include better patient selection; increased radiation damage delivery via dosimetry-based administered dose or use of α-emitters instead of β-emitters; or use of combinatorial approaches to overcome radioresistance mechanisms (innate or acquired), such as with novel hormonal agents, PARP inhibitors, or immunotherapy. In this article, we provide an overview of the currently available and forthcoming PSMA-based RNT and discuss approaches aimed at improving the efficacy and safety of PSMA-based RNT.

References

AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST AND DATA AVAILABILITY STATEMENT

Disclosures provided by the authors and data availability statement (if applicable) are available with this article at DOI https://doi.org/10.1200/EDBK_350946.

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc.

DAVID SCHUSTER

Employment: Ascend Imaging (I)

Consulting or Advisory Role: AIM Specialty Health; Syncona; Progenics; Global Medical Solutions

Research Funding: Blue Earth Diagnostics (Inst); Nihon Medi-Physics (Inst); Advanced Accelerator Applications (Inst); Telix Pharmaceuticals (Inst); FUJIFILM (Inst); Amgen (Inst)

Patents, Royalties, Other Intellectual Property: Inventor(s): Miller, Matthew (Oxford, GB), Gauden, David (Oxford, GB), Schuster, David (Atlanta, GA), Fanti, Stefano (Bologna, IT), Nanni, Cristina (Bologna, IT), Zanoni, Lucia (Bologna, IT), Willoch, Frode (Oslo, NO), Bogsrud, Trond Velde (Oslo, NO), Bach-Gansmo, Tore (Oslo, NO), Musto, Title: Imaging of metastatic or recurrent cancer Publication Number: US 20200316228 A1 Assignee: Blue Earth Diagnostics Limited (Oxford, GB) Filing Date: June 22, 2020 Granted: April 6, 2021

JEREMIE CALAIS

Honoraria: Radiomedix; Progenics; Advanced Accelerator Applications; EXINI Diagnostics

Consulting or Advisory Role: Blue Earth Diagnostics; Janssen; Progenics; Curium Pharma; GE Healthcare; Telix Pharmaceuticals; POINT Biopharma; Lantheus Medical Imaging

Speakers' Bureau: Telix Pharmaceuticals; IBA RadioPharma Solutions

Research Funding: Progenics

MICHAEL HOFMAN

Consulting or Advisory Role: Endocyte; Janssen; POINT Biopharma

Speakers' Bureau: Janssen; Mundipharma; Astellas Pharma; AstraZeneca

Research Funding: Endocyte (Inst); Advanced Accelerator Applications/Novartis (Inst)

Travel, Accommodations, Expenses: Ipsen; Genzyme; Janssen

No other potential conflicts of interest were reported.

REFERENCES

1.	Silver DA, Pellicer I, Fair WR, et al. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res. 1997;3:81-85. Medline, Google Scholar
2.	Eiber M, Fendler WP, Rowe SP, et al. Prostate-specific membrane antigen ligands for imaging and therapy. J Nucl Med. 2017;58(Suppl 2):67S-76S. Crossref, Medline, Google Scholar
3.	Fendler WP, Calais J, Eiber M, et al. Assessment of 68Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer: a prospective single-arm clinical trial. JAMA Oncol. 2019;5:856-863. Crossref, Medline, Google Scholar
4.	Morris MJ, Rowe SP, Gorin MA, et al; CONDOR Study Group. Diagnostic performance of 18F-DCFPyL-PET/CT in men with biochemically recurrent prostate cancer: results from the CONDOR phase III, multicenter study. Clin Cancer Res. 2021;27:3674-3682. Crossref, Medline, Google Scholar
5.	Sartor O, de Bono J, Chi KN, et al. Lutetium-177–PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021;385:1091-1103. Crossref, Medline, Google Scholar
6.	Chi KN, Metser U, Czernin J, et al. Study evaluating metastatic castrate resistant prostate cancer (mCRPC) treatment using 177Lu-PNT2002 PSMA therapy after second-line hormonal treatment (SPLASH) - Trial in progress. Clin Cancer Res. 2021;27:8s (suppl; abstr PO-077). Crossref, Medline, Google Scholar
7.	Tagawa ST, Milowsky MI, Morris M, et al. Phase II study of lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer. Clin Cancer Res. 2013;19:5182-5191. Crossref, Medline, Google Scholar
8.	Tagawa ST, Osborne J, Niaz MJ, et al. Dose-escalation results of a phase I study of 225Ac-J591 for progressive metastatic castration resistant prostate cancer (mCRPC). J Clin Oncol. 2020;38:6s (suppl; abstr 114). Google Scholar
9.	Hofman MS, Emmett L, Sandhu S, et al; TheraP Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group. [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet. 2021;397:797-804. Crossref, Medline, Google Scholar
10.	U.S. Food and Drug Administration. FDA approves Pluvicto for metastatic castration-resistant prostate cancer. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pluvicto-metastatic-castration-resistant-prostate-cancer. Accessed March 23, 2022. Google Scholar
11.	Manafi-Farid R, Harsini S, Saidi B, et al. Factors predicting biochemical response and survival benefits following radioligand therapy with [177Lu]Lu-PSMA in metastatic castrate-resistant prostate cancer: a review. Eur J Nucl Med Mol Imaging. 2021;48:4028-4041. Crossref, Medline, Google Scholar
12.	Gafita A, Calais J, Grogan TR, et al. Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study. Lancet Oncol. 2021;22:1115-1125. Crossref, Medline, Google Scholar
13.	Gafita A, Heck MM, Rauscher I, et al. Early prostate-specific antigen changes and clinical outcome following 177Lu-PSMA radionuclide treatment in patients with metastatic castration-resistant prostate cancer. J Nucl Med. 2020;61:1476-1483. Crossref, Medline, Google Scholar
14.	Barber TW, Singh A, Kulkarni HR, et al. Clinical outcomes of 177Lu-PSMA radioligand therapy in earlier and later phases of metastatic castration-resistant prostate cancer grouped by previous taxane chemotherapy. J Nucl Med. 2019;60:955-962. Crossref, Medline, Google Scholar
15.	Kessel K, Seifert R, Schäfers M, et al. Second line chemotherapy and visceral metastases are associated with poor survival in patients with mCRPC receiving 177Lu-PSMA-617. Theranostics. 2019;9:4841-4848. Crossref, Medline, Google Scholar
16.	Ahmadzadehfar H, Rahbar K, Baum RP, et al. Prior therapies as prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients treated with [177Lu]Lu-PSMA-617. A WARMTH multicenter study (the 617 trial). Eur J Nucl Med Mol Imaging. 2021;48:113-122. Crossref, Medline, Google Scholar
17.	Yadav MP, Ballal S, Bal C, et al. Efficacy and safety of 177Lu-PSMA-617 radioligand therapy in metastatic castration-resistant prostate cancer patients. Clin Nucl Med. 2020;45:19-31. Crossref, Medline, Google Scholar
18.	Derlin T, Sommerlath Sohns JM, Schmuck S, et al. Influence of short-term dexamethasone on the efficacy of 177 Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer. Prostate. 2020;80:619-631. Crossref, Medline, Google Scholar
19.	Suman S, Parghane RV, Joshi A, et al. Therapeutic efficacy, prognostic variables and clinical outcome of 177Lu-PSMA-617 PRLT in progressive mCRPC following multiple lines of treatment: prognostic implications of high FDG uptake on dual tracer PET-CT vis-à-vis Gleason score in such cohort. Br J Radiol. 2019;92:20190380. Crossref, Medline, Google Scholar
20.	Gadot M, Davidson T, Aharon M, et al. Clinical variables associated with PSA response to lutetium-177-PSMA ([177Lu]-PSMA-617) radionuclide treatment in men with metastatic castration-resistant prostate cancer. Cancers (Basel). 2020;12:1078. Crossref, Google Scholar
21.	Ferdinandus J, Eppard E, Gaertner FC, et al. Predictors of response to radioligand therapy of metastatic castrate-resistant prostate cancer with 177Lu-PSMA-617. J Nucl Med. 2017;58:312-319. Crossref, Medline, Google Scholar
22.	Ahmadzadehfar H, Schlolaut S, Fimmers R, et al. Predictors of overall survival in metastatic castration-resistant prostate cancer patients receiving [177Lu]Lu-PSMA-617 radioligand therapy. Oncotarget. 2017;8:103108-103116. Crossref, Medline, Google Scholar
23.	Gafita A, Fendler WP, Hui W, et al. Efficacy and safety of 177Lu-labeled prostate-specific membrane antigen radionuclide treatment in patients with diffuse bone marrow involvement: a multicenter retrospective study. Eur Urol. 2020;78:148-154. Crossref, Medline, Google Scholar
24.	Khreish F, Ghazal Z, Marlowe RJ, et al. 177 Lu-PSMA-617 radioligand therapy of metastatic castration-resistant prostate cancer: initial 254-patient results from a prospective registry (REALITY Study). Eur J Nucl Med Mol Imaging. 2022;49:1075-1085. Crossref, Medline, Google Scholar
25.	Yordanova A, Linden P, Hauser S, et al. The value of tumor markers in men with metastatic prostate cancer undergoing [177Lu]Lu-PSMA therapy. Prostate. 2020;80:17-27. Crossref, Medline, Google Scholar
26.	Heck MM, Tauber R, Schwaiger S, et al. Treatment outcome, toxicity, and predictive factors for radioligand therapy with 177Lu-PSMA-I&T in metastatic castration-resistant prostate cancer. Eur Urol. 2019;75:920-926. Crossref, Medline, Google Scholar
27.	Violet J, Sandhu S, Iravani A, et al. Long-term follow-up and outcomes of retreatment in an expanded 50-patient single-center phase II prospective trial of 177Lu-PSMA-617 theranostics in metastatic castration-resistant prostate cancer. J Nucl Med. 2020;61:857-865. Crossref, Medline, Google Scholar
28.	Rathke H, Holland-Letz T, Mier W, et al. Response prediction of 177Lu-PSMA-617 radioligand therapy using prostate-specific antigen, chromogranin A, and lactate dehydrogenase. J Nucl Med. 2020;61:689-695. Crossref, Medline, Google Scholar
29.	Grubmüller B, Senn D, Kramer G, et al. Response assessment using 68Ga-PSMA ligand PET in patients undergoing 177Lu-PSMA radioligand therapy for metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2019;46:1063-1072. Crossref, Medline, Google Scholar
30.	Kuo PH, Benson T, Messmann R, et al. Why we did what we did: PSMA-PET/CT selection criteria for the VISION trial. J Nucl Med. Epub 2022 Jan 27. Google Scholar
31.	Barrington SF, Kluge R. FDG PET for therapy monitoring in Hodgkin and non-Hodgkin lymphomas. Eur J Nucl Med Mol Imaging. 2017;44(Suppl 1):97-110. Crossref, Medline, Google Scholar
32.	Schwartz LH, Litière S, de Vries E, et al. RECIST 1.1—update and clarification: from the RECIST committee. Eur J Cancer. 2016;62:132-137. Crossref, Medline, Google Scholar
33.	Nyberg K. VISION: implementation of lutetium-177-PSMA-617 in metastatic castration-resistant prostate cancer approaches reality. ASCO Daily News. https://dailynews.ascopubs.org/do/10.1200/ADN.21.200630/full. Published June 9, 2021. Accessed October 26, 2021. Google Scholar
34.	Hotta M, Gafita A, Murthy V, et al. Predicting the outcome of mCPRC patients after Lu-177 PSMA therapy using semi-quantitative and visual criteria in baseline PSMA PET: an international multicenter retrospective study. J Clin Oncol. 2022;40:6s (suppl; abstr 32). Link, Google Scholar
35.	Milowsky MI, Nanus DM, Kostakoglu L, et al. Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer. J Clin Oncol. 2004;22:2522-2531. Link, Google Scholar
36.	Bander NH, Milowsky MI, Nanus DM, et al. Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J Clin Oncol. 2005;23:4591-4601. Link, Google Scholar
37.	Tagawa ST, Vallabhajosula S, Christos PJ, et al. Phase 1/2 study of fractionated dose lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 (177Lu-J591) for metastatic castration-resistant prostate cancer. Cancer. 2019;125:2561-2569. Crossref, Medline, Google Scholar
38.	Niaz MJ, Batra JS, Walsh RD, et al. Pilot study of hyperfractionated dosing of lutetium-177-labeled antiprostate-specific membrane antigen monoclonal antibody J591 (177Lu-J591) for metastatic castration-resistant prostate cancer. Oncologist. 2020;25:477-e895. Crossref, Medline, Google Scholar
39.	Vlachostergios PJ, Niaz MJ, Skafida M, et al. Imaging expression of prostate-specific membrane antigen and response to PSMA-targeted β-emitting radionuclide therapies in metastatic castration-resistant prostate cancer. Prostate. 2021;81:279-285. Crossref, Medline, Google Scholar
40.	Seifert R, Herrmann K, Kleesiek J, et al. Semiautomatically quantified tumor volume using 68Ga-PSMA-11 PET as a biomarker for survival in patients with advanced prostate cancer. J Nucl Med. 2020;61:1786-1792. Crossref, Medline, Google Scholar
41.	Seifert R, Seitzer K, Herrmann K, et al. Analysis of PSMA expression and outcome in patients with advanced prostate cancer receiving 177Lu-PSMA-617 radioligand therapy. Theranostics. 2020;10:7812-7820. Crossref, Medline, Google Scholar
42.	Seifert R, Kessel K, Schlack K, et al. PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [177Lu]Lu-PSMA-617 radioligand therapy in a bicentric analysis. Eur J Nucl Med Mol Imaging. 2021;48:1200-1210. Crossref, Medline, Google Scholar
43.	Khreish F, Ribbat K, Bartholomä M, et al. Value of combined PET IMAGING WITH [18F]FDG and [68Ga]Ga-PSMA-11 in mCRPC patients with worsening disease during [177Lu]Lu-PSMA-617 RLT. Cancers (Basel). 2021;13:4134. Crossref, Medline, Google Scholar
44.	Buteau JP, Martin AJ, Emmett L, et al. PSMA PET and FDG PET as predictors of response and prognosis in a randomized phase 2 trial of 177Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic, castration-resistant prostate cancer (mCRPC) progressing after docetaxel (TheraP ANZUP 1603). J Clin Oncol. 2022;40:6s(suppl; abstr 10). Google Scholar
45.	Nickols N, Anand A, Johnsson K, et al. aPROMISE: a novel automated PROMISE platform to standardize evaluation of tumor burden in 18F-DCFPyL images of veterans with prostate cancer. J Nucl Med. 2022;63:233-239. Crossref, Medline, Google Scholar
46.	Gafita A, Bieth M, Krönke M, et al. qPSMA: semiautomatic software for whole-body tumor burden assessment in prostate cancer using 68Ga-PSMA11 PET/CT. J Nucl Med. 2019;60:1277-1283. Crossref, Medline, Google Scholar
47.	Capobianco N, Gafita A, Platsch G, et al. Transfer learning of AI-based uptake classification from 18F-FDG PET/CT to 68Ga-PSMA-11 PET/CT for whole-body tumor burden assessment. J Nucl Med. 2020;61:s1 (supp; abstr 1411). Google Scholar
48.	Eiber M, Herrmann K, Calais J, et al. Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): proposed miTNM classification for the interpretation of PSMA-ligand PET/CT. J Nucl Med. 2018;59:469-478. Crossref, Medline, Google Scholar
49.	Hofman MS, Violet J, Hicks RJ, et al. [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. Lancet Oncol. 2018;19:825-833. Crossref, Medline, Google Scholar
50.	Calais J, Czernin J. PSMA expression assessed by PET imaging is a required biomarker for selecting patients for any PSMA-targeted therapy. J Nucl Med. 2021;62:1489-1491. Crossref, Medline, Google Scholar
51.	Sandach P, Kersting D, Weber M, et al. PSMA- and FDG-PET mismatch assessment for optimized selection of PSMA radioligand therapy candidates. Nucl Med (Stuttg). 2021;60:48. Google Scholar
52.	Thang SP, Violet J, Sandhu S, et al. Poor outcomes for patients with metastatic castration-resistant prostate cancer with low prostate-specific membrane antigen (PSMA) expression deemed ineligible for 177Lu-labelled PSMA radioligand therapy. Eur Urol Oncol. 2019;2:670-676. Crossref, Medline, Google Scholar
53.	Michalski K, Ruf J, Goetz C, et al. Prognostic implications of dual tracer PET/CT: PSMA ligand and [18F]FDG PET/CT in patients undergoing [177Lu]PSMA radioligand therapy. Eur J Nucl Med Mol Imaging. 2021;48:2024-2030. Crossref, Medline, Google Scholar
54.	Jadvar H. The VISION forward: recognition and implication of PSMA−/FDG+ mCRPC. J Nucl Med. Epub 2021 Dec 21. Google Scholar
55.	Parker C, Finkelstein SE, Michalski JM, et al. Efficacy and safety of radium-223 dichloride in symptomatic castration-resistant prostate cancer patients with or without baseline opioid use from the phase 3 ALSYMPCA trial. Eur Urol. 2016;70:875-883. Crossref, Medline, Google Scholar
56.	Kratochwil C, Giesel FL, Bruchertseifer F, et al. 213Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience. Eur J Nucl Med Mol Imaging. 2014;41:2106-2119. Crossref, Medline, Google Scholar
57.	Haberkorn U, Giesel F, Morgenstern A, et al. The future of radioligand therapy: α, β, or both? J Nucl Med. 2017;58:1017-1018. Crossref, Medline, Google Scholar
58.	Lee H. Relative efficacy of 225Ac-PSMA-617 and 177Lu-PSMA-617 in prostate cancer based on subcellular dosimetry. Mol Imaging Radionucl Ther. 2022;31:1-6. Crossref, Medline, Google Scholar
59.	Poty S, Francesconi LC, McDevitt MR, et al. α-Emitters for radiotherapy: from basic radiochemistry to clinical studies—part 1. J Nucl Med. 2018;59:878-884. Crossref, Medline, Google Scholar
60.	Gorin JB, Ménager J, Gouard S, et al. Antitumor immunity induced after α irradiation. Neoplasia. 2014;16:319-328. Crossref, Medline, Google Scholar
61.	Violet J, Jackson P, Ferdinandus J, et al. Dosimetry of 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer: correlations between pretherapeutic imaging and whole-body tumor dosimetry with treatment outcomes. J Nucl Med. 2019;60:517-523. Crossref, Medline, Google Scholar
62.	Sgouros G, Roeske JC, McDevitt MR, et al; SNM MIRD Committee. MIRD pamphlet no. 22 (abridged): radiobiology and dosimetry of alpha-particle emitters for targeted radionuclide therapy. J Nucl Med. 2010;51:311-328. Crossref, Medline, Google Scholar
63.	Emmett L, Willowson K, Violet J, et al. Lutetium 177 PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion of practical aspects of therapy. J Med Radiat Sci. 2017;64:52-60. Crossref, Medline, Google Scholar
64.	Tolkach Y, Kristiansen G. The heterogeneity of prostate cancer: a practical approach. Pathobiology. 2018;85:108-116. Crossref, Medline, Google Scholar
65.	Haffner MC, Zwart W, Roudier MP, et al. Genomic and phenotypic heterogeneity in prostate cancer. Nat Rev Urol. 2021;18:79-92. Crossref, Medline, Google Scholar
66.	Bakht MK, Derecichei I, Li Y, et al. Neuroendocrine differentiation of prostate cancer leads to PSMA suppression. Endocr Relat Cancer. 2019;26:131-146. Crossref, Medline, Google Scholar
67.	Wang HT, Yao YH, Li BG, et al. Neuroendocrine prostate cancer (NEPC) progressing from conventional prostatic adenocarcinoma: factors associated with time to development of NEPC and survival from NEPC diagnosis—a systematic review and pooled analysis. J Clin Oncol. 2014;32:3383-3390. Link, Google Scholar
68.	Lee JK, Bangayan NJ, Chai T, et al. Systemic surfaceome profiling identifies target antigens for immune-based therapy in subtypes of advanced prostate cancer. Proc Natl Acad Sci USA. 2018;115:E4473-E4482. Crossref, Medline, Google Scholar
69.	Bernhardt P, Forssell-Aronsson E, Jacobsson L, et al. Low-energy electron emitters for targeted radiotherapy of small tumours. Acta Oncol. 2001;40:602-608. Crossref, Medline, Google Scholar
70.	Hindié E, Zanotti-Fregonara P, Quinto MA, et al. Dose deposits from 90Y, 177Lu, 111In, and 161Tb in micrometastases of various sizes: implications for radiopharmaceutical therapy. J Nucl Med. 2016;57:759-764. Crossref, Medline, Google Scholar
71.	Smith-Jones PM, Vallabahajosula S, Goldsmith SJ, et al. In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen. Cancer Res. 2000;60:5237-5243. Medline, Google Scholar
72.	Behr TM, Béhé M, Stabin MG, et al. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab′ fragments in a human colonic cancer model. Cancer Res. 1999;59:2635-2643. Medline, Google Scholar
73.	Henriksen G, Fisher DR, Roeske JC, et al. Targeting of osseous sites with alpha-emitting 223Ra: comparison with the beta-emitter 89Sr in mice. J Nucl Med. 2003;44:252-259. Medline, Google Scholar
74.	Li Y, Russell PJ, Allen BJ. Targeted alpha-therapy for control of micrometastatic prostate cancer. Expert Rev Anticancer Ther. 2004;4:459-468. Crossref, Medline, Google Scholar
75.	Ritter MA, Cleaver JE, Tobias CA. High-LET radiations induce a large proportion of non-rejoining DNA breaks. Nature. 1977;266:653-655. Crossref, Medline, Google Scholar
76.	Kulkarni H, Singh A, Baum R. Response assessment to treatment with Lu-177 labeled PSMA inhibitor in patients with metastatic castration-resistant prostate cancer: differential response of bone versus lymph node lesions. J Nucl Med. 2016;57:s2 (suppl; abstr 1547). Google Scholar
77.	Satapathy S, Mittal BR, Sood A. Visceral metastases as predictors of response and survival outcomes in patients of castration-resistant prostate cancer treated with 177Lu-labeled prostate-specific membrane antigen radioligand therapy: a systematic review and meta-analysis. Clin Nucl Med. 2020;45:935-942. Crossref, Medline, Google Scholar
78.	Paschalis A, Sheehan B, Riisnaes R, et al. Prostate-specific membrane antigen heterogeneity and DNA repair defects in prostate cancer. Eur Urol. 2019;76:469-478. Crossref, Medline, Google Scholar
79.	Zhang J, Kulkarni HR, Singh A, et al. Complete regression of lung metastases in a patient with metastatic castration-resistant prostate cancer using 177Lu-PSMA radioligand therapy. Clin Nucl Med. 2020;45:e48-e50. Crossref, Medline, Google Scholar
80.	Brady L, Kriner M, Coleman I, et al. Inter- and intra-tumor heterogeneity of metastatic prostate cancer determined by digital spatial gene expression profiling. Nat Commun. 2021;12:1426. Crossref, Medline, Google Scholar
81.	Pond GR, Sonpavde G, de Wit R, et al. The prognostic importance of metastatic site in men with metastatic castration-resistant prostate cancer. Eur Urol. 2014;65:3-6. Crossref, Medline, Google Scholar
82.	Colletier PJ, Ashoori F, Cowen D, et al. Adenoviral-mediated p53 transgene expression sensitizes both wild-type and null p53 prostate cancer cells in vitro to radiation. Int J Radiat Oncol Biol Phys. 2000;48:1507-1512. Crossref, Medline, Google Scholar
83.	Stuparu AD, Capri JR, Meyer CAL, et al. Mechanisms of resistance to prostate-specific membrane antigen-targeted radioligand therapy in a mouse model of prostate cancer. J Nucl Med. 2021;62:989-995. Crossref, Medline, Google Scholar
84.	Kratochwil C, Giesel FL, Heussel CP, et al. Patients resistant against PSMA-targeting α-radiation therapy often harbor mutations in DNA damage-repair-associated genes. J Nucl Med. 2020;61:683-688. Crossref, Medline, Google Scholar
85.	de Bono J, Mateo J, Fizazi K, et al. Olaparib for metastatic castration-resistant prostate cancer. N Engl J Med. 2020;382:2091-2102. Crossref, Medline, Google Scholar
86.	Ravi Kumar AS, Hofman MS. Mechanistic insights for optimizing PSMA radioligand therapy. Clin Cancer Res. 2020;26:2774-2776. Crossref, Medline, Google Scholar
87.	Kiniwa Y, Miyahara Y, Wang HY, et al. CD8+ Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer. Clin Cancer Res. 2007;13:6947-6958. Crossref, Medline, Google Scholar
88.	Miller AM, Lundberg K, Ozenci V, et al. CD4+CD25high T cells are enriched in the tumor and peripheral blood of prostate cancer patients. J Immunol. 2006;177:7398-7405. Crossref, Medline, Google Scholar
89.	May KF Jr, Gulley JL, Drake CG, et al. Prostate cancer immunotherapy. Clin Cancer Res. 2011;17:5233-5238. Crossref, Medline, Google Scholar
90.	Sharma P, Pachynski RK, Narayan V, et al. Nivolumab plus ipilimumab for metastatic castration-resistant prostate cancer: preliminary analysis of patients in the CheckMate 650 trial. Cancer Cell. 2020;38:489-499.e3. Crossref, Medline, Google Scholar
91.	Beer TM, Kwon ED, Drake CG, et al. Randomized, double-blind, phase III trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant prostate cancer. J Clin Oncol. 2017;35:40-47. Link, Google Scholar
92.	Kwon ED, Drake CG, Scher HI, et al; CA184-043 Investigators. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2014;15:700-712. Crossref, Medline, Google Scholar
93.	Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443-2454. Crossref, Medline, Google Scholar
94.	Hansen AR, Massard C, Ott PA, et al. Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study. Ann Oncol. 2018;29:1807-1813. Crossref, Medline, Google Scholar
95.	Keam SP, Halse H, Nguyen T, et al. High dose-rate brachytherapy of localized prostate cancer converts tumors from cold to hot. J Immunother Cancer. 2020;8:e000792. Crossref, Medline, Google Scholar
96.	Reits EA, Hodge JW, Herberts CA, et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med. 2006;203:1259-1271. Crossref, Medline, Google Scholar
97.	Brown JS, Sundar R, Lopez J. Combining DNA damaging therapeutics with immunotherapy: more haste, less speed. Br J Cancer. 2018;118:312-324. Crossref, Medline, Google Scholar
98.	Kwan EM, Spain L, Anton A, et al. Avelumab combined with stereotactic ablative body radiotherapy in metastatic castration-resistant prostate cancer: the phase 2 ICE-PAC clinical trial. Eur Urol. 2022;81:253-262. Crossref, Medline, Google Scholar
99.	Aggarwal RR, Sam SL, Koshkin VS, et al. Immunogenic priming with 177Lu-PSMA-617 plus pembrolizumab in metastatic castration resistant prostate cancer (mCRPC): a phase 1b study. J Clin Oncol. 2021;39:15s (suppl; abstr 5053). Link, Google Scholar
100.	Sandhu SK, Joshua AM, Emmett L, et al. PRINCE: interim analysis of the phase Ib study of 177Lu-PSMA-617 in combination with pembrolizumab for metastatic castration resistant prostate cancer (mCRPC). Ann Oncol. 2021;32:s5(suppl; abstr 577O). Medline, Google Scholar
101.	Lord CJ, Ashworth A. The DNA damage response and cancer therapy. Nature. 2012;481:287-294. Crossref, Medline, Google Scholar
102.	Purohit NK, Shah RG, Adant S, et al. Potentiation of 177Lu-octreotate peptide receptor radionuclide therapy of human neuroendocrine tumor cells by PARP inhibitor. Oncotarget. 2018;9:24693-24706. Crossref, Medline, Google Scholar
103.	Nonnekens J, van Kranenburg M, Beerens CE, et al. Potentiation of peptide receptor radionuclide therapy by the PARP inhibitor olaparib. Theranostics. 2016;6:1821-1832. Crossref, Medline, Google Scholar
104.	Cullinane C, Waldeck K, Kirby L, et al. Enhancing the anti-tumour activity of 177Lu-DOTA-octreotate radionuclide therapy in somatostatin receptor-2 expressing tumour models by targeting PARP. Sci Rep. 2020;10:10196. Crossref, Medline, Google Scholar
105.	Yang Y, Luo J, Chen X, et al. CDK4/6 inhibitors: a novel strategy for tumor radiosensitization. J Exp Clin Cancer Res. 2020;39:188. Crossref, Medline, Google Scholar
106.	Crumbaker M, Pathmanandavel S, Yam AO, et al. Phase I/II trial of the combination of 177lutetium prostate specific membrane antigen 617 and idronoxil (NOX66) in men with end-stage metastatic castration-resistant prostate cancer (LuPIN). Eur Urol Oncol. 2021;4:963-970. Crossref, Medline, Google Scholar
107.	Chan TG, O’Neill E, Habjan C, et al. Combination strategies to improve targeted radionuclide therapy. J Nucl Med. 2020;61:1544-1552. Crossref, Medline, Google Scholar
108.	Yordanova A, Ahrens H, Feldmann G, et al. Peptide receptor radionuclide therapy combined with chemotherapy in patients with neuroendocrine tumors. Clin Nucl Med. 2019;44:e329-e335. Crossref, Medline, Google Scholar
109.	Rohrer Bley C, Furmanova P, Orlowski K, et al. Microtubule stabilising agents and ionising radiation: multiple exploitable mechanisms for combined treatment. Eur J Cancer. 2013;49:245-253. Crossref, Medline, Google Scholar
110.	Golden EB, Formenti SC, Schiff PB. Taxanes as radiosensitizers. Anticancer Drugs. 2014;25:502-511. Crossref, Medline, Google Scholar
111.	Kelly MP, Lee ST, Lee FT, et al. Therapeutic efficacy of 177Lu-CHX-A″-DTPA-hu3S193 radioimmunotherapy in prostate cancer is enhanced by EGFR inhibition or docetaxel chemotherapy. Prostate. 2009;69:92-104. Crossref, Medline, Google Scholar
112.	Batra JS, Niaz MJ, Whang YE, et al. Phase I trial of docetaxel plus lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 (177Lu-J591) for metastatic castration-resistant prostate cancer. Urol Oncol. 2020;38:848.e9-848.e16. Crossref, Google Scholar
113.	Meller B, Bremmer F, Sahlmann CO, et al. Alterations in androgen deprivation enhanced prostate-specific membrane antigen (PSMA) expression in prostate cancer cells as a target for diagnostics and therapy. EJNMMI Res. 2015;5:66. Crossref, Medline, Google Scholar
114.	Evans MJ, Smith-Jones PM, Wongvipat J, et al. Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen. Proc Natl Acad Sci USA. 2011;108:9578-9582. Crossref, Medline, Google Scholar
115.	Hope TA, Truillet C, Ehman EC, et al. 68Ga-PSMA-11 PET imaging of response to androgen receptor inhibition: first human experience. J Nucl Med. 2017;58:81-84. Crossref, Medline, Google Scholar
116.	Emmett L, Yin C, Crumbaker M, et al. Rapid modulation of PSMA expression by androgen deprivation: serial 68Ga-PSMA-11 PET in men with hormone-sensitive and castrate-resistant prostate cancer commencing androgen blockade. J Nucl Med. 2019;60:950-954. Crossref, Medline, Google Scholar
117.	Staniszewska M, Fragoso Costa P, Eiber M, et al. Enzalutamide enhances PSMA expression of PSMA-low prostate cancer. Int J Mol Sci. 2021;22:7431. Crossref, Medline, Google Scholar
118.	Suman S, Parghane RV, Joshi A, et al. Combined 177Lu-PSMA-617 PRLT and abiraterone acetate versus 177Lu-PSMA-617 PRLT monotherapy in metastatic castration-resistant prostate cancer: an observational study comparing the response and durability. Prostate. 2021;81:1225-1234. Crossref, Medline, Google Scholar
119.	Emmett L, Subramaniam S, Zhang AY, et al. ENZA-p: a randomized phase II trial using PSMA as a therapeutic agent and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901). J Clin Oncol. 2021;39:6s (suppl; abstr TPS177). Link, Google Scholar
120.	Dhiantravan N, Violet J, Eapen R, et al. Clinical trial protocol for LuTectomy: a single-arm study of the dosimetry, safety, and potential benefit of 177Lu-PSMA-617 prior to prostatectomy. Eur Urol Focus. 2021;7:234-237. Crossref, Medline, Google Scholar
121.	Dhiantravan N, Emmett L, Joshua AM, et al. UpFrontPSMA: a randomized phase 2 study of sequential 177Lu-PSMA-617 and docetaxel vs docetaxel in metastatic hormone-naïve prostate cancer (clinical trial protocol). BJU Int. 2021;128:331-342. Crossref, Medline, Google Scholar
122.	Sartor AO, Tagawa ST, Saad F, et al. PSMAddition: a phase 3 trial to compare treatment with 177Lu-PSMA-617 plus standard of care (SOC) versus SOC alone in patients with metastatic hormone-sensitive prostate cancer. J Clin Oncol. 2022;40:6s (suppl; abstr TPS210). Google Scholar
123.	Sartor AO, Morris MJ, Chi KN, et al. PSMAfore: a phase 3 study to compare 177Lu-PSMA-617 treatment with a change in androgen receptor pathway inhibitor in taxane-naïve patients with metastatic castration-resistant prostate cancer. J Clin Oncol. 2022;40:6s (suppl; abstr TPS211). Google Scholar
124.	Sartor O, Fougère C, Essler M, et al. 177Lu-prostate-specific membrane antigen ligand after 223Ra treatment in men with bone-metastatic castration-resistant prostate cancer: real-world clinical experience. J Nucl Med. 2022;63:410-414. Crossref, Medline, Google Scholar
125.	Calopedos RJS, Chalasani V, Asher R, et al. Lutetium-177-labelled anti-prostate-specific membrane antigen antibody and ligands for the treatment of metastatic castrate-resistant prostate cancer: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2017;20:352-360. Crossref, Medline, Google Scholar
126.	Kratochwil C, Giesel FL, Stefanova M, et al. PSMA-targeted radionuclide therapy of metastatic castration-resistant prostate cancer with 177Lu-labeled PSMA-617. J Nucl Med. 2016;57:1170-1176. Crossref, Medline, Google Scholar
127.	Ahmadzadehfar H, Eppard E, Kürpig S, et al. Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer. Oncotarget. 2016;7:12477-12488. Crossref, Medline, Google Scholar
128.	Radchenko V, Morgenstern A, Jalilian AR, et al. Production and supply of α-particle-emitting radionuclides for targeted α-therapy. J Nucl Med. 2021;62:1495-1503. Crossref, Medline, Google Scholar
129.	McDevitt MR, Ma D, Lai LT, et al. Tumor therapy with targeted atomic nanogenerators. Science. 2001;294:1537-1540. Crossref, Medline, Google Scholar
130.	Robertson AKH, Ramogida CF, Schaffer P, et al. Development of 225Ac radiopharmaceuticals: TRIUMF perspectives and experiences. Curr Radiopharm. 2018;11:156-172. Crossref, Medline, Google Scholar
131.	Yadav MP, Ballal S, Sahoo RK, et al. Efficacy and safety of 225Ac-PSMA-617 targeted alpha therapy in metastatic castration-resistant prostate cancer patients. Theranostics. 2020;10:9364-9377. Crossref, Medline, Google Scholar
132.	Kratochwil C, Bruchertseifer F, Rathke H, et al. Targeted α-therapy of metastatic castration-resistant prostate cancer with 225Ac-PSMA-617: dosimetry estimate and empiric dose finding. J Nucl Med. 2017;58:1624-1631. Crossref, Medline, Google Scholar
133.	Sathekge M, Bruchertseifer F, Vorster M, et al. Predictors of overall and disease-free survival in metastatic castration-resistant prostate cancer patients receiving 225Ac-PSMA-617 radioligand therapy. J Nucl Med. 2020;61:62-69. Crossref, Medline, Google Scholar
134.	Ballal S, Yadav MP, Sahoo RK, et al. 225Ac-PSMA-617-targeted alpha therapy for the treatment of metastatic castration-resistant prostate cancer: a systematic review and meta-analysis. Prostate. 2021;81:580-591. Crossref, Medline, Google Scholar
135.	van der Doelen MJ, Mehra N, van Oort IM, et al. Clinical outcomes and molecular profiling of advanced metastatic castration-resistant prostate cancer patients treated with 225Ac-PSMA-617 targeted alpha-radiation therapy. Urol Oncol. 2021;39:729.e7-729.e16. Crossref, Google Scholar
136.	Feuerecker B, Tauber R, Knorr K, et al. Activity and adverse events of actinium-225-PSMA-617 in advanced metastatic castration-resistant prostate cancer after failure of lutetium-177-PSMA. Eur Urol. 2021;79:343-350. Crossref, Medline, Google Scholar
137.	Kratochwil C, Bruchertseifer F, Rathke H, et al. Targeted α-therapy of metastatic castration-resistant prostate cancer with 225Ac-PSMA-617: swimmer-plot analysis suggests efficacy regarding duration of tumor control. J Nucl Med. 2018;59:795-802. Crossref, Medline, Google Scholar
138.	Rosar F, Hau F, Bartholomä M, et al. Molecular imaging and biochemical response assessment after a single cycle of Ac-PSMA-617/Lu-PSMA-617 tandem therapy in mCRPC patients who have progressed on Lu-PSMA-617 monotherapy. Theranostics. 2021;11:4050-4060. Crossref, Medline, Google Scholar
139.	Khreish F, Ebert N, Ries M, et al. 225Ac-PSMA-617/177Lu-PSMA-617 tandem therapy of metastatic castration-resistant prostate cancer: pilot experience. Eur J Nucl Med Mol Imaging. 2020;47:721-728. Crossref, Medline, Google Scholar
140.	Kiess AP, Minn I, Vaidyanathan G, et al. (2S)-2-(3-(1-Carboxy-5-(4-211At-astatobenzamido)pentyl)ureido)-pentanedioic acid for PSMA-targeted α-particle radiopharmaceutical therapy. J Nucl Med. 2016;57:1569-1575. Crossref, Medline, Google Scholar
141.	Banerjee SR, Minn I, Kumar V, et al. Preclinical evaluation of 203/212Pb-labeled low-molecular-weight compounds for targeted radiopharmaceutical therapy of prostate cancer. J Nucl Med. 2020;61:80-88. Crossref, Medline, Google Scholar
142.	Hammer S, Hagemann UB, Zitzmann-Kolbe S, et al. Preclinical efficacy of a PSMA-targeted thorium-227 conjugate (PSMA-TTC), a targeted alpha therapy for prostate cancer. Clin Cancer Res. 2020;26:1985-1996. Crossref, Medline, Google Scholar
143.	Nonnekens J, Chatalic KL, Molkenboer-Kuenen JD, et al. 213Bi-labeled prostate-specific membrane antigen-targeting agents induce DNA double-strand breaks in prostate cancer xenografts. Cancer Biother Radiopharm. 2017;32:67-73. Crossref, Medline, Google Scholar
144.	Alcocer-Ávila ME, Ferreira A, Quinto MA, et al. Radiation doses from 161Tb and 177Lu in single tumour cells and micrometastases. EJNMMI Phys. 2020;7:33. Crossref, Medline, Google Scholar
145.	Müller C, Umbricht CA, Gracheva N, et al. Terbium-161 for PSMA-targeted radionuclide therapy of prostate cancer. Eur J Nucl Med Mol Imaging. 2019;46:1919-1930. Crossref, Medline, Google Scholar
146.	Kiess AP, Minn I, Chen Y, et al. Auger radiopharmaceutical therapy targeting prostate-specific membrane antigen. J Nucl Med. 2015;56:1401-1407. Crossref, Medline, Google Scholar
147.	Shen CJ, Minn I, Hobbs RF, et al. Auger radiopharmaceutical therapy targeting prostate-specific membrane antigen in a micrometastatic model of prostate cancer. Theranostics. 2020;10:2888-2896. Crossref, Medline, Google Scholar
148.	Sandhu S, Guo C, Hofman MS. Radionuclide therapy in prostate cancer: from standalone to combination PSMA theranostics. J Nucl Med. 2021;62:1660-1668. Crossref, Google Scholar
149.	Niaz MJ, Skafida M, Osborne J, et al. Comparison of prostate-specific membrane antigen (PSMA)-targeted radionuclide therapy (TRT) with lutetium-177 (177LU) via antibody J591 vs small molecule ligand PSMA-617. J Urol. 2020;203(Suppl 4):e367 (suppl; abstr PD16-11). Google Scholar
150.	McDevitt MR, Barendswaard E, Ma D, et al. An alpha-particle emitting antibody ([213Bi]J591) for radioimmunotherapy of prostate cancer. Cancer Res. 2000;60:6095-6100. Medline, Google Scholar
151.	Benešová M, Umbricht CA, Schibli R, et al. Albumin-binding PSMA ligands: optimization of the tissue distribution profile. Mol Pharm. 2018;15:934-946. Crossref, Medline, Google Scholar
152.	NCT05219500. Targeted Alpha Therapy With 225Actinium-PSMA-I&T of Castration-resISTant Prostate Cancer (TATCIST). https://clinicaltrials.gov/ct2/show/NCT05219500. Accessed April 21, 2022. Google Scholar
153.	Weineisen M, Schottelius M, Simecek J, et al. 68Ga- and 177Lu-labeled PSMA I&T: optimization of a PSMA-targeted theranostic concept and first proof-of-concept human studies. J Nucl Med. 2015;56:1169-1176. Crossref, Medline, Google Scholar
154.	Yusufi N, Wurzer A, Herz M, et al. Comparative preclinical biodistribution, dosimetry, and endoradiotherapy in metastatic castration-resistant prostate cancer using 19F/177Lu-rhPSMA-7.3 and 177Lu-PSMA I&T. J Nucl Med. 2021;62:1106-1111. Crossref, Medline, Google Scholar
155.	Banerjee SR, Lisok A, Minn I, et al. Preclinical evaluation of 213Bi- and 225Ac-labeled low-molecular-weight compounds for radiopharmaceutical therapy of prostate cancer. J Nucl Med. 2021;62:980-988. Crossref, Medline, Google Scholar
156.	NCT03822871. A Trial of CTT1403 for Metastatic Castration Resistant Prostate Cancer. https://clinicaltrials.gov/ct2/show/NCT03822871. Accessed April 21, 2022. Google Scholar
157.	NCT04509557. Ludotadipep Treatment in Patients With Metastatic Castration-resistant Prostate Cancer. https://clinicaltrials.gov/ct2/show/NCT04509557. Accessed April 21, 2022. Google Scholar
158.	NCT03490838. 177Lu-PSMA-R2 in Patients With PSMA Positive Progressive, Metastatic, Castration Resistant Prostate Cancer (PROter). https://clinicaltrials.gov/ct2/show/NCT03490838. Accessed April 21, 2022. Google Scholar
159.	NCT03780075. Lu177-EB-PSMA617 Radionuclide Treatment in Patients With Metastatic Castration-resistant Prostate Cancer. https://clinicaltrials.gov/ct2/show/NCT03780075. Accessed April 21, 2022. Google Scholar
160.	NCT03276572. Phase I Trial of 225Ac-J591 in Patients With mCRPC. https://clinicaltrials.gov/ct2/show/NCT03276572. Accessed April 21, 2022. Google Scholar
161.	NCT04506567. Fractionated and Multiple Dose 225Ac-J591 for Progressive mCRPC. https://clinicaltrials.gov/ct2/show/NCT04506567. Accessed April 21, 2022. Google Scholar
162.	NCT04576871. Re-treatment 225Ac-J591 for mCRPC. https://clinicaltrials.gov/ct2/show/NCT04576871. Accessed April 21, 2022. Google Scholar
163.	Feng T, Wang J, Cheng K, et al. IL13Rα1 prevents a castration resistant phenotype of prostate cancer by targeting hexokinase 2 for ubiquitin-mediated degradation. Cancer Biol Med. Epub 2021 Oct 18. Crossref, Google Scholar
164.	Timmermand OV, Elgqvist J, Beattie KA, et al. Preclinical efficacy of hK2 targeted [177Lu]hu11B6 for prostate cancer theranostics. Theranostics. 2019;9:2129-2142. Crossref, Medline, Google Scholar
165.	Bicak M, Lückerath K, Kalidindi T, et al. Genetic signature of prostate cancer mouse models resistant to optimized hK2 targeted α-particle therapy. Proc Natl Acad Sci USA. 2020;117:15172-15181. Crossref, Medline, Google Scholar
166.	Burnell SEA, Spencer-Harty S, Howarth S, et al. Utilisation of the STEAP protein family in a diagnostic setting may provide a more comprehensive prognosis of prostate cancer. PLoS One. 2019;14:e0220456. Crossref, Medline, Google Scholar
167.	NCT01774071. Study of 89Zr-DFO-MSTP2109A in Patients With Prostate Cancer. https://clinicaltrials.gov/ct2/show/NCT01774071. Accessed April 21, 2022. Google Scholar
168.	Beltran H, Tagawa ST, Park K, et al. Challenges in recognizing treatment-related neuroendocrine prostate cancer. J Clin Oncol. 2012;30:e386-e389. Link, Google Scholar
169.	Korsen JA, Kalidindi TM, Khitrov S, et al. Molecular imaging of neuroendocrine prostate cancer by targeting delta-like ligand 3. J Nucl Med. Epub 2022 Jan 22. Crossref, Google Scholar
170.	Liu C, Liu T, Zhang J, et al. Excellent response to 177Lu-DOTATATE peptide receptor radionuclide therapy in a patient with progressive metastatic castration-resistant prostate cancer with neuroendocrine differentiation after 177Lu-PSMA therapy. Clin Nucl Med. 2019;44:876-878. Crossref, Medline, Google Scholar
171.	Gofrit ON, Frank S, Meirovitz A, et al. PET/CT with 68Ga-DOTA-TATE for diagnosis of neuroendocrine: differentiation in patients with castrate-resistant prostate cancer. Clin Nucl Med. 2017;42:1-6. Crossref, Medline, Google Scholar
172.	Usmani S, Ahmed N, Marafi F, et al. Molecular imaging in neuroendocrine differentiation of prostate cancer: 68Ga-PSMA versus 68Ga-DOTA NOC PET-CT. Clin Nucl Med. 2017;42:410-413. Crossref, Medline, Google Scholar

PSMA, petscan, 68Ga–prostate-specific membrane antigen (PSMA) ligand PET imaging, uitzaaiingen op afstand, radiotherapie, bestraling

Plaats een reactie ...

1 Reactie op "PSMA gerichte PET scan bij mannen met verhoogde PSA is effectieve manier in ontdekken van plaats van tumoren. Bij uitzaaiingen op afstand heeft bestralen van bekkengebied geen zin."

e.valstar :
14/12/2019
Prachtig dat het allemaal eerder en duidelijker te zien is, maar waar is de randomised controlled clinical trial die aantoont dat daarop gericht eerder behandelen door bestralen de prognose verbetert? wie kan mij dat onderzoek tonen? Ik ken alleen maar aanwijzingen dat dit eerder in kaart brengen de prognose niet verbetert.

Comment